EN DE
Watch CellBion Co., Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

CellBion Co., Ltd (308430) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of CellBion Co., Ltd stock KRW 7,412, price KRW 11,880, that is 37.6% below the price, quality 31 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

CC CellBion Co., Ltd logo Thin data Nov 10, 2026

CellBion Co., Ltd

308430 · KQ
Very expensive, weak quality

Our calculation puts a fair price 38% below what the stock costs today.

Low debt
Revenue last quarter +17% vs. a year ago.
Expensive Growth (revenue 3y +3.3 %/yr in KRW)
Mixed vs. peers (5/9)
Moderate moat 47/100
Fair value 7,412 KRW · Strongly overvalued
Quality 31/100
Negative free cash flow
Thin data
Estimate
Watch CellBion Co., Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

40,150 KRW 10,110 KRW Fair Value 7,412 KRW Oct 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

25‑month range 10,110 KRW – 40,150 KRW · fair‑value band 5,559 KRW – 9,265 KRW · the 11,880 KRW price screens above the 7,412 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow CellBion Co. in your weekly email

Every Wednesday you see whether CellBion Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products.

Show moreShow less

Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage.

It is involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications.

CellBion Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.

Stock analysis

CellBion Co., Ltd (308430) currently trades at 11,880 KRW, while our estimate is 7,412 KRW, 38% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 5,559 KRW (bear) to 9,265 KRW (bull), the price of 11,880 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

CellBion Co., Ltd reported revenue of 1.9B KRW in FY2025 versus 917M KRW in FY2021, a compound +20.7%/yr. Reported net income was −7.6B KRW in FY2025.

Key figures

Market cap 152B KRW (≈ $114M) Micro · P/E ratio 21.2 · P/S ratio 70.0 · EPS (TTM) 600.46 KRW · Return on equity 24.8% · Return on assets (EBIT) −32.3% (5-year average) · Operating margin −560% · Revenue (TTM) 2.1B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (medium confidence).

What moves the price

The share trades about 70% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −38%, 308430 screens richer than that median.

Fair Value

Bear 5,559 KRW Fair Value 7,412 KRW Bull 9,265 KRW
Price 11,880 KRW · Downside -37.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 18
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 79
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 16
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 5
Distance to the 52-week high, does not count
New shares 80
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 31/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−15.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−496.3% (2021) → −423.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

308430 screens overvalued: fair value 38% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare CellBion Co., Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −37.6% · Below median
Profitability
Return on equity (12 months) 24.8% · Top 25%
Return on assets −21.5% · Above median
Growth and dividend
Revenue growth (quarter YoY) 16.7% · Above median
Balance sheet
Debt / equity 0.04× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 21.2× · Cheaper than median
P/B 6.68× · Priciest 25%
P/S (12 months) 70.98× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)84 · sector 0
PAST (return on equity)99 · sector 0
HEALTH (low debt)98 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 308430
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 308430
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 308430
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 308430
argenx SE ARGX $971.55 $908.40 −7% vs 308430
CSL Limited CSL A$201.68 A$181.40 −10% vs 308430
Moderna, Inc MRNA $250.83 $158.70 −37% vs 308430
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 308430
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 308430
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 308430

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CellBion Co., Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "CellBion Co., Ltd Fair Value". https://www.fairvalue-calculator.com/stock/308430

Frequently asked questions

Is CellBion Co., Ltd (308430) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 7,412 KRW versus a price of 11,880 KRW, about 38% lower (overvalued).
What is the fair value of 308430?
Our estimate for CellBion Co., Ltd is 7,412 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 11,880 KRW.
What is the quality score of 308430?
CellBion Co., Ltd has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for CellBion Co., Ltd (308430)?
Our calculated price target is the estimate of 7,412 KRW (as of Nov 10, 2026). Cautious scenario 5,559 KRW, optimistic scenario 9,265 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the CellBion Co., Ltd stock forecast for 2026?
Our estimate puts fair value at 7,412 KRW, about 38% lower versus a price of 11,880 KRW (overvalued). Cautious scenario 5,559 KRW, optimistic scenario 9,265 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of CellBion Co., Ltd (308430)?
CellBion Co., Ltd reported trailing-twelve-month revenue of about 2.1B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of CellBion Co., Ltd (308430)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CellBion Co., Ltd it is 7,412 KRW per share (as of Nov 10, 2026), against a price of 11,880 KRW.
Is CellBion Co., Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 308430 trades above its calculated fair value: price 11,880 KRW, fair value 7,412 KRW, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 308430?
No. The price is what the market pays today (11,880 KRW); the fair value is what the company's own numbers justify (7,412 KRW). For CellBion Co., Ltd the two are 4,468 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is CellBion Co., Ltd worth?
The market values CellBion Co., Ltd at about 152B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 11,880 KRW; our models calculate a fair value of 7,412 KRW per share.
What do the bullish and bearish scenarios say about 308430?
Our models span a range for CellBion Co., Ltd: cautious scenario 5,559 KRW, base 7,412 KRW, optimistic 9,265 KRW per share (as of Nov 10, 2026, price 11,880 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 308430?
CellBion Co., Ltd trades at a price-to-earnings ratio of 21.2 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 7,412 KRW is built from several models across several years. Other multiples: P/B 6.7, P/S 71.0.
How solid is the balance sheet of CellBion Co., Ltd (308430)?
Balance-sheet figures for CellBion Co., Ltd (as of Nov 10, 2026): return on equity 24.8%, debt of 0.04 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 308430 from its 52-week high?
CellBion Co., Ltd trades at 11,880 KRW, about 70% below its 52-week high of 40,150 KRW and 12% above the low of 10,570 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 7,412 KRW is for.
Which stocks are comparable to CellBion Co., Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is CellBion Co., Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price 11,880 KRW, calculated fair value 7,412 KRW (−38%), Quality Score 31/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. CellBion Co., Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of CellBion Co., Ltd (308430)?
The closing price on Nov 10, 2026 was 11,880 KRW. Our estimate is 7,412 KRW, about 38% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with CellBion Co., Ltd right now?
The price sits above even our optimistic bull case (9,265 KRW). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of CellBion Co., Ltd

How large is the market capitalisation of CellBion Co., Ltd (308430)?
The market capitalisation of CellBion Co., Ltd is 152B KRW (≈ $114M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of CellBion Co., Ltd (308430)?
The price-to-sales ratio of CellBion Co., Ltd is 70.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of CellBion Co., Ltd (308430)?
Earnings per share at CellBion Co., Ltd are 600.46 KRW (price ÷ EPS = P/E 21.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of CellBion Co., Ltd (308430)?
The return on equity (ROE) of CellBion Co., Ltd is 24.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of CellBion Co., Ltd (308430)?
On an EBIT basis the return on assets of CellBion Co., Ltd is −32.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of CellBion Co., Ltd (308430)?
The operating margin of CellBion Co., Ltd is −560% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at CellBion Co., Ltd (308430)?
Revenue at CellBion Co., Ltd is growing +16.7% versus a year earlier (3y avg +3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does CellBion Co., Ltd (308430) generate?
The free cash flow of CellBion Co., Ltd is −7.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does CellBion Co., Ltd (308430) carry?
The net debt of CellBion Co., Ltd is 245M KRW (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch CellBion Co., Ltd in the live analysis

One click puts CellBion Co., Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.